loading page

Thirty-two COVID-19 cases preventively vaccinated with MMR: all mild course
  • Désirée Larenas-Linnemann
Désirée Larenas-Linnemann
Hospital Médica Sur
Author Profile

Abstract

We would like to report here on our clinical observations in 212 subjects, vaccinated in our Center since the start of the Coronavirus disease-2019 (COVID-19) pandemic, with the mumps-measles-rubeola (MMR) vaccine and of whom thirty-two have presented COVID-19, all with a remarkably mild course.In the light of the COVID-19 pandemic, observing the highly contagious and virulent nature of the virus, new to mankind and for which no actual treatment nor vaccination exists, we have been searching for methods to enhance innate immunity. Moreover, the pandemic started in our country just after a rise in measles cases had motivated the Ministry of Health to recommend measles re-vaccination. Aware of the existence of trained immunity we decided to apply this concept and from March 2020 onward recommend MMR vaccination, but with extra emphasis among family members of COVID-19 cases. In June 2020 the American Society for Microbiology (AMS) speculated in a press-release that “the MMR vaccine could serve as a preventive measure to dampen …. COVID-19 infection.”

Peer review status:ACCEPTED

05 Aug 2020Submitted to Allergy
07 Aug 2020Submission Checks Completed
07 Aug 2020Assigned to Editor
09 Aug 2020Reviewer(s) Assigned
10 Aug 2020Review(s) Completed, Editorial Evaluation Pending
14 Aug 20201st Revision Received
17 Aug 2020Submission Checks Completed
17 Aug 2020Assigned to Editor
17 Aug 2020Review(s) Completed, Editorial Evaluation Pending
19 Aug 20202nd Revision Received
20 Aug 2020Submission Checks Completed
20 Aug 2020Assigned to Editor
20 Aug 2020Review(s) Completed, Editorial Evaluation Pending
21 Aug 20203rd Revision Received
24 Aug 2020Assigned to Editor
24 Aug 2020Submission Checks Completed
26 Aug 2020Review(s) Completed, Editorial Evaluation Pending
28 Aug 2020Editorial Decision: Accept